---
title: "IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295950027.md"
description: "Focused on oncology, the company advances three key assets: lacutamab (targeting CTCL with strong Phase 2 data and a major Sobi partnership), monalizumab (in Phase 3 for NSCLC with AstraZeneca), and IPH4502 (a novel ADC in Phase 1). Significant milestones and data readouts are expected in H2 2026.Original document: Innate Pharma SA Class A [IPH] Slides Release — Aug. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-14T14:45:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295950027.md)
  - [en](https://longbridge.com/en/news/295950027.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295950027.md)
generator: "portal-rs"
---

# IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026

Focused on oncology, the company advances three key assets: lacutamab (targeting CTCL with strong Phase 2 data and a major Sobi partnership), monalizumab (in Phase 3 for NSCLC with AstraZeneca), and IPH4502 (a novel ADC in Phase 1). Significant milestones and data readouts are expected in H2 2026.

Original document: Innate Pharma SA Class A \[IPH\] Slides Release — Aug. 14 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [IPHA.US](https://longbridge.com/en/quote/IPHA.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value](https://longbridge.com/en/news/296923180.md)
- [China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial](https://longbridge.com/en/news/297148879.md)
- [MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026](https://longbridge.com/en/news/296862063.md)
- [BREAKINGVIEWS-AstraZeneca's blocked M&A signals tough CEO finale](https://longbridge.com/en/news/296766497.md)
- [Akari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast](https://longbridge.com/en/news/297190869.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**